Open AccessCOMPARISON OF THREE CHEMOTHERAPY REGIMENS TO THE DECREASE IN LEUKOCYTES AND THE INCIDENCE RATE OF NEUTROPENIA IN PATIENTS WITH NASOPHARYNGEAL CANCER AT DR. HASAN SADIKIN GENERAL HOSPITAL BANDUNG
Author(s) -
Nadiya Nurul Afifah,
Ajeng Diantini,
Pratiwi Pratiwi
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10s2.20774
Subject(s) - carboplatin , medicine , neutropenia , cisplatin , chemotherapy , cancer , regimen , nasopharyngeal carcinoma , incidence (geometry) , febrile neutropenia , oncology , gastroenterology , surgery , radiation therapy , physics , optics
Nasopharyngeal cancer is the ninth most common cancer in indonesia. The death of cancer patients is not only caused by the cancer itself, but also several other factors such as the side effects of chemotherapy. Some side effects that occurred are decrease in leukocytes and incidence of neutropenia. Neutropenia is the highest hematological toxicity caused by chemotherapy treatment which has final manifestation are death from systemic infection. The purpose of this study is to compare three chemotherapy regimens in causing a decrease in leukocytes and the incidence of neutropenia to the patients with nasopharyngeal cancer in RSUP. Dr. Hasan Sadikin Bandung. The three chemotherapy regimens compared in this study are cisplatin, cisplatin / 5-FU, and carboplatin / Paclitaxel. This research is an analytic observational study with retrospective data collection and cross-sectional analytic design. The data were obtained from the medical records of inpatients with nasopharyngeal cancer during January -December 2015, total data 86 nasopharyngeal carcinoma patient[s] (>18 y.o, female and male) data had been analyzed in this study. The results showed that there is no significant differences (p> 0.05) in the three regimens in causing the reduction of leukocyte (p=0.327) and the average of Absolute Neutrofil Count (p=0.240). The percentage of neutropenia incidence in cisplatin regimen is 8.3%, in cisplatin / 5-FU is 14.3%, and in carboplatin / paclitaxel is 18.6%.